Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
NBI-1076986 by Neurocrine Biosciences for Movement Disorders: Likelihood of Approval
NBI-1076986 is under clinical development by Neurocrine Biosciences and currently in Phase I for Movement Disorders. According to GlobalData, Phase...
Data Insights
Risk adjusted net present value: What is the current valuation of Neurocrine Biosciences's NBI-1076986?
NBI-1076986 is a small molecule commercialized by Neurocrine Biosciences, with a leading Phase I program in Movement Disorders. According to...